DAVID ALLEN: Open Payments
NPI 1295884021 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,325 in 78 payments from 25 companies in 2025. Trend: 2023 $1,084 · 2024 $1,516 · 2025 $1,325
Food & beverage: $1,325
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $296 |
| Novo Nordisk Inc | 7 | $115 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $106 |
| AstraZeneca Pharmaceuticals LP | 6 | $94 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $62 |
| Lilly USA, LLC | 3 | $57 |
| Novartis Pharmaceuticals Corporation | 3 | $54 |
| Radius Health, Inc. | 3 | $52 |
| Medtronic, Inc. | 1 | $48 |
| Abbott Laboratories | 2 | $45 |
Products named: VRAYLAR, Kerendia, UBRELVY, XIFAXAN, LEQVIO, Tymlos, Wegovy, AIRSUPRA.
Industry payments across NE — which companies pay providers there.
